257 related articles for article (PubMed ID: 23362135)
1. Tumor localization and biochemical response to cure in tumor-induced osteomalacia.
Chong WH; Andreopoulou P; Chen CC; Reynolds J; Guthrie L; Kelly M; Gafni RI; Bhattacharyya N; Boyce AM; El-Maouche D; Crespo DO; Sherry R; Chang R; Wodajo FM; Kletter GB; Dwyer A; Collins MT
J Bone Miner Res; 2013 Jun; 28(6):1386-98. PubMed ID: 23362135
[TBL] [Abstract][Full Text] [Related]
2. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
3. Reports of 17 Chinese patients with tumor-induced osteomalacia.
Yu WJ; He JW; Fu WZ; Wang C; Zhang ZL
J Bone Miner Metab; 2017 May; 35(3):298-307. PubMed ID: 27085966
[TBL] [Abstract][Full Text] [Related]
4. Comparison of
Yu HN; Liu L; Chen QS; He Q; Li YS; Wang Y; Gao S
Orthop Surg; 2021 May; 13(3):791-798. PubMed ID: 33709632
[TBL] [Abstract][Full Text] [Related]
5. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.
Hu FK; Yuan F; Jiang CY; Lv DW; Mao BB; Zhang Q; Yuan ZQ; Wang Y
Chin J Cancer; 2011 Nov; 30(11):794-804. PubMed ID: 22035861
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.
Perri M; Erba P; Volterrani D; Lazzeri E; Boni G; Grosso M; Mariani G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):323-33. PubMed ID: 18480741
[TBL] [Abstract][Full Text] [Related]
8. Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia.
Westerberg PA; Olauson H; Toss G; Wikström B; Morales O; Linde T; Jonsson K; Ljunggren O; Larsson TE
Endocr Pract; 2008 Apr; 14(3):362-7. PubMed ID: 18463045
[TBL] [Abstract][Full Text] [Related]
9. Utility of 18F-AlF-NOTA-Octreotide PET/CT in the Localization of Tumor-Induced Osteomalacia.
Long T; Hou J; Yang N; Zhou M; Li Y; Li J; Tang Y; Chen D; Hu S
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4202-e4209. PubMed ID: 33864458
[TBL] [Abstract][Full Text] [Related]
10.
El-Maouche D; Sadowski SM; Papadakis GZ; Guthrie L; Cottle-Delisle C; Merkel R; Millo C; Chen CC; Kebebew E; Collins MT
J Clin Endocrinol Metab; 2016 Oct; 101(10):3575-3581. PubMed ID: 27533306
[TBL] [Abstract][Full Text] [Related]
11. Tumor-induced osteomalacia.
Florenzano P; Gafni RI; Collins MT
Bone Rep; 2017 Dec; 7():90-97. PubMed ID: 29021995
[TBL] [Abstract][Full Text] [Related]
12. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
[TBL] [Abstract][Full Text] [Related]
13. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
[TBL] [Abstract][Full Text] [Related]
14. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
15.
Li J
Front Endocrinol (Lausanne); 2024; 15():1400751. PubMed ID: 38887276
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case.
Dupond JL; Mahammedi H; Prié D; Collin F; Gil H; Blagosklonov O; Ricbourg B; Meaux-Ruault N; Kantelip B
Bone; 2005 Mar; 36(3):375-8. PubMed ID: 15777669
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Positive Presurgical FDG PET/CT in the Evaluation of Tumor-Induced Osteomalacia.
Wang P; Zhang S; Huo L; Jing H; Li F
Clin Nucl Med; 2021 Mar; 46(3):214-219. PubMed ID: 33351512
[TBL] [Abstract][Full Text] [Related]
18. [Value of
Zhang S; Wang L; Wang T; Xing HQ; Huo L; Li F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):757-764. PubMed ID: 30606385
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance and impact on patient management of
Paquet M; Gauthé M; Zhang Yin J; Nataf V; Bélissant O; Orcel P; Roux C; Talbot JN; Montravers F
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1710-1720. PubMed ID: 29532101
[TBL] [Abstract][Full Text] [Related]
20. Tumor-induced osteomalacia: experience from a South American academic center.
González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
